Prognostic indicators of outcome of in superior vena cava syndrome in lung cancer: a retrospective descriptive study in Sunpasitthiprasong Hospital

Abstract

Objectives: The study aims to examine prognostic indicators in patients diagnosed with Superior Vena Cava Syndrome (SVCS) due to lung cancer in the Department of Internal Medicine at Sunpasitthiprasong Hospital.
Method: This study utilized a retrospective observational study, collecting data from medical records of 129 patients diagnosed with Superior Vena Cava Syndrome (SVCS) due to lung cancer. The data spanned from January 2560 to December 2564. The statistical method of Kaplan-Meier curve was employed to analyze overall survival (OS) rates. Additionally, the Log-rank test was used to compare survival rates among different factors, including treatment goals, histology, treatment options, and treatment delay.
Results: The study included 129 participants, with 78.3% was male. The average age of the participants was 64.38 ± 13.89 years. The Eastern Cooperative Oncology Group (ECOG) performance status of 1 was most prevalent among the participants, accounting for 61.2%. The overall survival time for the entire group was found to be 59.82 months (95% CI: 48.78-70.86). Regarding the treatment options, the average survival time for patients who received radiotherapy was 30.65 months (95%CI: 25.89-35.41). On the other hand, patients who underwent chemotherapy had an average survival time of 64.6 months (P-value = 0.173, 95% CI: 44.62-84.59). Concerning treatment delay, patients with treatment delay less than 7 days had an average survival time of 57.79 months (95% CI: 43.11-72.48). Conversely, patients with treatment delay of 7 days or more had average survival time of 18.18 months (P-value = 0.648, 95% CI: 16.35-20.0). For patients with Adenocarcinoma had an average survival time of 19.73 months (95%CI: 16.62-22.85). While, patients with SCLC (Small cell lung cancer) had an average survival time of 14.45 months (P-value = 0.325, 95% CI: 9.15-19.74). Regarding the goal of treatment, patients who received Radical treatment had an average survival time of 12.12 months (95%CI: 6.69-17.55) .And patients who received Palliative treatment had average survival time of 66.33 months (P-value < 0.001, 95% CI: 57.3-75.35).
Conclusion: In patients with Superior Vena Cava Syndrome (SVCS) due to lung cancer, There is no statistically significant differences were observed in treatment options, treatment delay, or histology cell type. The only significant factor affecting survival rates was the goal of treatment, which had an impact on disease prognosis.